Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir
Multicenter Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir Fix Dose combination_The HepNet Acute HCV-V Study
Sponsor: German Center for Infection Research
A PHASE2 clinical study on Acute Hepatitis C and Hepatitis C, this trial is completed. The trial is conducted by German Center for Infection Research and has accumulated 14 data snapshots since 2019. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 9 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Apr 2020 — Jun 2020 [monthly]
Recruiting PHASE2
-
Dec 2019 — Apr 2020 [monthly]
Recruiting PHASE2
-
Sep 2019 — Dec 2019 [monthly]
Recruiting PHASE2
-
Aug 2019 — Sep 2019 [monthly]
Recruiting PHASE2
-
Jul 2019 — Aug 2019 [monthly]
Recruiting PHASE2
-
Jun 2019 — Jul 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2019 — Jun 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- German Center for Infection Research
- Gilead Sciences
- Hannover Medical School
- HepNet Study House, German Liverfoundation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Berlin, Germany , Bonn, Germany , Cologne, Germany , Essen, Germany , Frankfurt, Germany , Friedrichshain, Germany , Hamburg, Germany , Hanover, Germany , Leipzig, Germany , München, Germany and 2 more locations